Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant for migraine prevention in children and adolescents
2021-005246-15Phase 3Active
- Sponsor
- Biohaven Ltd.
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in migraine and migraine without aura comparing Rimegepant with Placebo (2 arms). Primary endpoint: Change from baseline in mean number of migraine days per month. Started Apr 2022; status: active.
02
Drugs
rimegepant
03
Conditions
migrainemigraine without aura
Beyond the preview
Go deeper on 2021-005246-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005246-15.